Brookline Capital Markets Comments on CLRB Q2 Earnings

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Analysts at Brookline Capital Markets issued their Q2 2026 earnings per share estimates for shares of Cellectar Biosciences in a research report issued on Sunday, July 12th. Brookline Capital Markets analyst K. Dolliver anticipates that the biopharmaceutical company will post earnings per share of ($0.63) for the quarter. Brookline Capital Markets has a “Strong-Buy” rating on the stock. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($2.34) per share. Brookline Capital Markets also issued estimates for Cellectar Biosciences’ Q3 2026 earnings at ($0.50) EPS and Q4 2026 earnings at ($0.59) EPS.

Several other research analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Cellectar Biosciences to a “hold” rating in a report on Saturday, June 20th. LADENBURG THALM/SH SH initiated coverage on Cellectar Biosciences in a research report on Friday, May 15th. They issued a “buy” rating for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Monday, April 20th. Finally, Roth Capital reissued a “buy” rating and issued a $11.00 price objective on shares of Cellectar Biosciences in a research note on Tuesday, May 5th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Cellectar Biosciences Price Performance

Shares of NASDAQ CLRB opened at $2.63 on Wednesday. The stock has a market cap of $21.01 million, a P/E ratio of -0.39 and a beta of 0.55. The firm’s 50-day simple moving average is $2.80 and its 200 day simple moving average is $2.99. Cellectar Biosciences has a fifty-two week low of $2.20 and a fifty-two week high of $6.52.

Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings results on Thursday, May 14th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.88) by $0.55.

Institutional Trading of Cellectar Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in shares of Cellectar Biosciences in the fourth quarter worth about $36,000. DRW Securities LLC raised its holdings in shares of Cellectar Biosciences by 114.2% during the fourth quarter. DRW Securities LLC now owns 45,190 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 24,089 shares during the period. Geode Capital Management LLC raised its holdings in shares of Cellectar Biosciences by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 28,636 shares of the biopharmaceutical company’s stock valued at $84,000 after acquiring an additional 3,744 shares during the period. Sequoia Financial Advisors LLC lifted its position in shares of Cellectar Biosciences by 135.1% in the 4th quarter. Sequoia Financial Advisors LLC now owns 25,350 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 14,567 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new stake in shares of Cellectar Biosciences in the 3rd quarter valued at approximately $104,000. Institutional investors and hedge funds own 16.41% of the company’s stock.

Key Stories Impacting Cellectar Biosciences

Here are the key news stories impacting Cellectar Biosciences this week:

• Positive Sentiment: Cellectar published Phase 1 data for iopofosine I 131 showing manageable safety and preliminary antitumor activity, including stable disease or better in most evaluable patients, which supports continued development. Article Title
• Positive Sentiment: Brookline Capital Markets upgraded Cellectar Biosciences to Strong-Buy, reinforcing a more bullish outlook on the stock. Article Title
• Neutral Sentiment: Brookline also issued quarterly and full-year EPS estimates that were in line with the broader consensus, which is not a major surprise but keeps attention on the company’s expected losses and development timeline.
• Negative Sentiment: Short interest in CLRB reportedly rose sharply, signaling that some traders remain skeptical and that volatility could stay elevated. Article Title

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc is a clinical‐stage biopharmaceutical company focused on the development of targeted cancer therapies and imaging agents. The company’s proprietary phospholipid drug conjugate (PDC) technology platform is designed to selectively deliver therapeutic and diagnostic payloads to malignant cells while sparing healthy tissue. Through its PDC approach, Cellectar aims to improve the efficacy and safety profile of traditional treatments like chemotherapy and radiotherapy.

Its lead therapeutic candidate, CLR 131, is a radioisotope‐labeled PDC being evaluated in Phase II clinical trials for relapsed or refractory B‐cell malignancies, including multiple myeloma and non‐Hodgkin lymphoma.